Table of Contents
Table of Contents
1 Table Of Contents 2
1.1 List Of Tables 11
1.2 List Of Figures 14
2 Introduction 16
2.1 What Is This Report
About? 16
2.2 Definitions 16
2.2.1 Drug delivery devices 16
2.2.1.1 Needle-free Injections 16
2.2.1.2 Inhalation Systems 16
2.2.1.3 Infusion Systems 17
3 Healthcare Sector Review 18
3.1
Healthcare Expenditure 18
3.2 Healthcare Infrastructure 23
3.2.1
Healthcare Personnel Data 25
3.2.2 Healthcare Facilities Data 28
4
Drug Delivery Devices in United States. 30
4.1 Drug Delivery Devices
Overall Revenues (2000-2012) 30
4.2 Drug Delivery Devices Overall Volume
(2000-2012) 36
4.3 Drug Delivery Devices Overall Company Shares
(2005-2006) 37
5 Inhalation System in United States 39
5.1 Inhalation
Systems Overall Revenues (2000-2012) 39
5.1.1 Metered Dose Inhalation
Systems Overall Revenues (2000-2012) 43
5.1.2 Dry Powder Inhalation
Systems Overall Revenues (2000-2012) 45
5.2 Inhalation Systems Overall
Volume (2000-2012) 47
5.2.1 Metered Dose Inhalation Systems Overall Volume
(2000-2012) 49
5.2.2 Dry Powder Inhalation Systems Overall Volume
(2000-2012) 51
5.3 Inhalation Systems Average Price (2000-2012) 53
5.3.1 Metered Dose Inhalation Systems Average Price (2000-2012) 53
5.3.2
Dry Powder Inhalation Systems Average Price (2000-2012) 55
5.4 Inhalation
Systems Distribution Share (2005-2006) 57
5.5 Inhalation Systems Company
Share (2005-2006) 58
6 Infusion System in United States 59
6.1
Infusion Systems Overall Revenues (2000-2012) 59
6.1.1 Infusion Disposable
Sets Infusion System Overall Revenues (2000-2012) 63
6.1.2 Infusion Pumps
Infusion System Overall Revenue (2000-2012) 65
6.1.3 Syringe Pumps
Infusion System Overall Revenue (2000-2012) 67
6.2 Infusion Systems
Overall Volume (2000-2012) 69
6.2.1 Infusion Disposable Sets Overall
Volume (2000-2012) 70
6.2.2 Infusion Pumps Overall Volume (2000-2012)
72
6.2.3 Syringe Pumps Overall Volume (2000-2012) 74
6.3 Infusion
Systems Average Price (2000-2012) 76
6.3.1 Infusion Pumps Average Price
(2000-2012) 76
6.3.2 Syringe Pumps Average Price (2000-2012) 78
6.3.3
Infusion Disposable Sets Average Price (2000-2012) 80
6.4 Infusion Systems
Distribution Share (2005-2006) 82
6.5 Infusion Systems Company Share
(2005-2006) 83
7 Needle Free Injections in United States 84
7.1 Needle
Free Injections Overall Revenue (2000-2012) 84
7.2 Needle Free Injections
Category Volume (2000-2012) 86
7.3 Needle Free Injections Average Price
(2000-2012) 88
7.4 Needle Free Injections Distribution Share (2005-2006)
90
7.5 Needle Free Injections Company Share (2005-2006) 91
8
AstraZeneca PLC Company Profile 92
8.1 Company Overview 92
8.2
Business Overview 92
8.2.1 Products 93
8.2.2 History 94
8.3
Locations And Subsidiaries 94
8.4 Financial Deals Landscape 96
8.4.1
AstraZeneca Completes $6,900 Million Private Placement 96
8.4.2
AstraZeneca Acquires MedImmune 97
8.4.3 AstraZeneca Acquires Biologics
Manufacturing Facility From DSM Biologics 99
8.4.4 AstraZeneca Acquires
Arrow Therapeutics 100
8.4.5 AstraZeneca Signs An Agreement With Palatin
Technologies 102
8.4.6 AstraZeneca Signs An Agreement With Bristol-Myers
Squibb 103
8.4.7 AstraZeneca Signs An Agreement With Cubist
Pharmaceuticals 105
8.4.8 AstraZeneca Signs An Agreement With Par
Pharmaceutical 106
8.4.9 Schering Signs An Agreement With AstraZeneca
108
8.4.10 AstraZeneca Signs An Agreement With Pozen 109
8.4.11
AstraZeneca Signs An Agreement With Abbott 111
8.4.12 AstraZeneca To Sell
Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience
112
8.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals 114
8.4.14
AstraZeneca Acquires A Stake In Protherics 116
8.4.15 AstraZeneca Signs An
Agreement With Targacept 117
8.4.16 AstraZeneca Signs An Agreement With
AtheroGenics 118
8.4.17 AstraZeneca UK Signs An Agreement With Protherics
120
8.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma
Aktiengesellschaft 122
8.4.19 AstraZeneca Signs An Agreement With Astex
Therapeutics 123
8.4.20 AstraZeneca Signs An Agreement With Avanir
Pharmaceuticals 125
8.4.21 AstraZeneca And Royal Cosun Sells Joint Venture
Advanta To Syngenta 126
8.4.22 AstraZeneca Completes Private Placement Of
$750 million 128
8.4.23 AstraZeneca Prices EUR750 Million Private
Placement 130
8.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And
Euro750 Million Eurobond Private Placement 131
8.5 Recent Developments
132
8.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical
Pricing Case 132
8.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive
Director 133
8.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement
Actions in Response to Crestor ANDAs 133
8.5.4 Sep 28, 2007: AstraZeneca
Appoints New CFO 134
8.5.5 Jul 25, 2007: AstraZeneca Appoints New Board
Member 134
8.5.6 Jun 06, 2007: AstraZeneca CFO Resigns 134
8.5.7 Feb
22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site
135
8.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For
Major Research And Development 135
8.5.9 Jan 22, 2007: AstraZeneca Makes
$100 Million Research Investment In Boston 136
9 GlaxoSmithKline plc
Company Profile 137
9.1 Company Overview 137
9.2 Business Overview
137
9.2.1 Products 138
9.2.2 History 138
9.3 Locations And
Subsidiaries 140
9.4 Financial Deals Landscape 141
9.4.1
GlaxoSmithKline Acquires CNS 141
9.4.2 Bayer HealthCare Acquires Pritor
Business From GlaxoSmithKline 142
9.4.3 CNS To Merge With GlaxoSmithKline
144
9.5 Recent Developments 145
9.5.1 Mar 19, 2008: GSK charitable
support valued at GBP282 million in 2007 145
9.5.2 Feb 07, 2008: Full-year
results announcement 2007 145
9.5.3 Dec 19, 2007: GlaxoSmithKline And
Santaris Enter Global R&D Alliance 146
9.5.4 Dec 10, 2007: GlaxoSmithKline
And OncoMed Form Strategic Alliance To Develop Cancer Stem Cell Antibody
Therapeutics 146
9.5.5 Dec 07, 2007: GlaxoSmithKline Announces Board And
Management Changes 147
10 3M Company Profile 148
10.1 Company Overview
148
10.2 Business Overview 148
10.2.1 Consumer and Office 148
10.2.2 Display and Graphics 148
10.2.3 Electro and Communications 149
10.2.4 Health Care 149
10.2.5 Industrial and Transportation 150
10.2.6
Safety, Security and Protection Services 151
10.2.7 Products 151
10.3
Value Chain Analysis 153
10.3.1 Manufacturing 153
10.3.2 Product
Development 154
10.3.3 Sales and Marketing 154
10.4 SWOT Analysis
155
10.4.1 3M Company Strengths 155
10.4.2 3M Company Weaknesses
156
10.4.3 3M Company Opportunities 156
10.4.4 3M Company Threats
157
10.5 Financial and Operational Review 158
10.6 Locations And
Subsidiaries 160
10.7 Financial Deals Landscape 161
10.7.1 3M Canada
Acquires Les Entreprises Solumed 161
10.7.2 3M Acquires Bondo 163
10.7.3 3M Acquires Lingualcare 165
10.7.4 3M Acquires Abzil Industria E
Comercio 166
10.7.5 3M Acquires Neo Plast 168
10.7.6 3M Acquires
Assets Of DMS Chile 170
10.7.7 3M Acquires Business Of Innovative Paper
Technologies 172
10.7.8 3M Acquires Powell 174
10.7.9 Gen-Probe Signs
An Agreement With 3M Company 176
10.7.10 3M Acquires Acolyte Biomedica
178
10.7.11 3M Acquires Sealed Air Corp.' S Interest In Polymask Corp.
180
10.7.12 3M Sells Its Pharmaceutical Business To Meda AB 182
10.7.13 3M Acquires SoftMed Systems 184
10.7.14 3M Sells its
Pharmaceuticals Business to Graceway 186
10.7.15 Gen-Probe Signs An
Agreement With 3M 188
10.7.16 3M Sells its Pharmaceutical Operations in
the Asia Pacific Region to Ironbridge Capital and Archer Capital 191
10.7.17 3M Acquires Biotrace International 192
10.7.18 Ekahau Secures $16
Million In Additional Funding 194
10.7.19 3M Acquires Brontes Technologies
197
10.7.20 3M acquires Nylonge Corp 200
10.7.21 3M Signs An Agreement
With ClozeX Medical 201
10.7.22 3M Acquires OMNII Oral Pharmaceuticals
203
10.7.23 3M Sells Pharmaceutical Operations In The United States To
Graceway 205
10.7.24 3M Sells Pharmaceutical Business In Europe To Meda AB
208
10.7.25 3M Sells Pharmaceutical Operations In The Asia Pacific To
Ironbridge and Archer Capital 210
10.7.26 3M Acquires Accuspray
Application Technologies Inc. 213
10.7.27 3M to acquire Rochford Thompson
Equipment 215
10.7.28 3M To Acquire Aearo Technologies From Permira
217
10.7.29 Permira To Sell Aearo Technologies To 3M 219
10.8 Recent
Developments 221
10.8.1 Mar 31, 2008: HighJump Software Introduces Survey
Management Solution for Direct Store Delivery Businesses 221
10.8.2 Mar
24, 2008: Brazil' s Companhia de Transmissao de Energia Eletrica Paulista
Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State
222
10.8.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in
Asia 223
10.8.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business
In North Asia 223
10.8.5 Nov 12, 2007: 3M Declares Quarterly Dividend
223
10.8.6 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery
224
10.8.7 Aug 13, 2007: 3M Declares Quarterly Dividend 224
10.8.8 May
08, 2007: 3M Declares Quarterly Dividend 224
10.8.9 Apr 30, 2007:
Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests 224
11
Baxter International Company Profile 225
11.1 Company Overview 225
11.2 Business Overview 225
11.2.1 BioScience 225
11.2.2 Medication
Delivery 225
11.2.3 Renal 226
11.2.4 Products 226
11.2.5 History
227
11.3 Value Chain Analysis 230
11.3.1 Manufacturing 230
11.3.2
Product Development 230
11.3.3 Sales and Marketing 231
11.4 SWOT
Analysis 232
11.4.1 Baxter International Inc. Strengths 232
11.4.2
Baxter International Inc. Weaknesses 233
11.4.3 Baxter International Inc.
Opportunities 233
11.4.4 Baxter International Inc. Threats 233
11.5
Financial and Operational Review 235
11.6 Locations And Subsidiaries
237
11.7 Financial Deals Landscape 238
11.7.1 Baiyunshan And Baxter
Form A Joint Venture In China 238
11.7.2 Baxter Signs Licensing Agreement
With Intercytex And Spinal Restoration 240
11.7.3 Baxter Sells Transfusion
Therapies Business to Texas Pacific and Maverick Capital 241
11.7.4 B.
Braun Acquires Renal Therapy Business Of Baxter 243
11.7.5 Innovata signs
a license agreement with Baxter International 245
11.7.6 Kuros Biosurgery
Signs An Agreement With Baxter International 246
11.7.7 Gambro Signs An
Agreement With Baxter 248
11.7.8 Baxter Healthcare And Gambro Enter Into
An Agreement 249
11.7.9 Baxter and Cerus Enter Into Agreement With BioOne
for Commercialization Of INTERCEPT Blood System 251
11.7.10 Baxter
International And Kaketsuken Enter Into Agreement 253
11.7.11 Baxter To
Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful 254
11.8
Recent Developments 256
11.8.1 Jan 24, 2008: Baxter Achieves Record Sales
and Earnings for Full-Year 2007 256
11.8.2 Dec 18, 2007: Baxter Elects CFO
258
11.8.3 Nov 13, 2007: Baxter Declares Quarterly Dividend 258
11.8.4
Aug 01, 2007: Baxter Elects New Board Director 258
11.8.5 Jul 31, 2007:
Baxter Announces Quarterly Dividend 259
11.8.6 Mar 13, 2007: Baxter
Declares Additional Share Repurchase Authorization 259
11.8.7 Feb 13,
2007: Baxter Announces Quarterly Dividend 259
11.8.8 Nov 28, 2006: Baxter
Announces Annual Dividend 259
11.8.9 Sep 14, 2006: Baxter Appoints
President, Baxter Latin America 260
11.9 Baxter International Inc.
Pipeline Products 260
11.9.1 Next-Generation Home Hemodialysis Machine
260
11.9.1.1 Product Overview 260
11.9.1.2 Product Description 261
11.9.1.3 Product Status 261
11.9.1.4 Product Milestone 261
12 Hospira
Company Profile 262
12.1 Company Overview 262
12.2 Business Overview
262
12.2.1 Injectable Pharmaceutical Custom Manufacturing Services Product
Category 262
12.2.2 Other products, including critical care devices
Product Category 262
12.2.3 Specialty Injectable Pharmaceuticals Product
Category 262
12.2.4 Products 262
12.3 History 263
12.4 Value Chain
Analysis 265
12.4.1 Manufacturing 265
12.4.2 Product Development
266
12.4.3 Sales and Marketing 266
12.5 SWOT Analysis 267
12.5.1
Hospira, Inc. Strengths 267
12.5.2 Hospira, Inc. Weaknesses 268
12.5.3
Hospira, Inc. Opportunities 268
12.5.4 Hospira, Inc. Threats 269
12.6
Financial and Operational Review 270
12.7 Locations And Subsidiaries
272
12.8 Financial Deals Landscape 273
12.8.1 Hospira Acquires Mayne
Pharma 273
12.8.2 Hospira Signs An Agreement With STADA 275
12.8.3
Hospira Acquires Physiometrix 276
12.8.4 ICU Medical Acquires Salt Lake
City Manufacturing Facility From Hospira 278
12.9 Recent Developments
280
12.9.1 Feb 28, 2007: Hospira Reports 2006 Results 280
12.9.2 Oct
31, 2006: Hospira Elects New Board Member 280
12.9.3 Aug 11, 2006: Hospira
Appoints New CFO 281
13 Regulation System 282
13.1 Medical Equipment
Approval Process 282
13.1.1 Pre-market Approval Process 283
13.1.2
Intended use and Indications for use 283
13.1.3 Predicate Device 283
13.1.4 Safe and Effective 284
13.1.5 Other Category Devices 286
13.1.6
Post-Market Approval Process 287
13.1.7 Compliance and Enforcement 287
13.1.8 Registration Fee 288
13.1.9 Approval Time 288
14 Pricing and
Reimbursement 289
14.1 Government Policies 289
14.2 Private Insurance
290
14.3 Diagnosis Related Groups (DRG) 291
15 Distribution Structure
292
15.1 Distribution Structure 292
16 APPENDIX 293
16.1
Methodology 293
16.2 Currency Conversion 294
16.3 Contact Us 295
16.4 Disclaimer 295
View Cart
